Patents Represented by Attorney David H. Vance

Find this attorney in the Justia Lawyer Directory

  • Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
    Patent number: 6967208
    Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: November 22, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Donald J. P. Pinto, Mimi L. Quan, Michael J. Orwat, Yun-Long Li, Wei Han, Jennifer X. Qiao, Patrick Y. S. Lam, Stephanie L. Koch
  • Guanidine mimics as factor Xa inhibitors
    Patent number: 6906070
    Abstract: The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: June 14, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Patrick Y. Lam, Charles G. Clark, Celia Dominguez, John M. Fevig, Qi Han, Renhua Li, Donald J. P. Pinto, James R. Pruitt, Mimi L. Quan
  • Nitrogen containing heterobicycles as factor Xa inhibitors
    Patent number: 6858616
    Abstract: The present application describes nitrogen containing heterobicyclics and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: February 22, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: John M. Fevig, Joseph Cacciola, Charles G. Clark, Qi Han, Patrick Yuk Sun Lam, Donald J. P. Pinto, James R. Pruitt, Mimi L. Quan, Karen A. Rossi
  • Cyclic hydroxamic acid as metalloproteinase inhibitors
    Patent number: 6858626
    Abstract: The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: February 22, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Chu-Biao Xue, Carl P. Decicco, Xiaohua He
  • 1,1-disubstituted cyclic inhibitors of matrix metalloproteases and TNF-&agr;
    Patent number: 6825215
    Abstract: The present application describes novel 1,1-disubsituted cyclic derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-8 membered non-aromatic ring consisting of: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, NR2, S, S(O), and S(O)2 and the other variables are defined in the present specification, which are useful as metalloprotease and as TNF-&agr; inhibitors.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: November 30, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Xiao-Tao Chen, Chu-Biao Xue
  • Fused heterocyclic inhibitors of factor Xa
    Patent number: 6790845
    Abstract: This invention relates generally to a novel class of fused heterocyclic compounds of the Formula (I) or Formula (II): or pharmaceutically acceptable salt forms thereof, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: September 14, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Irina C. Jacobson, Mimi L. Quan, Ruth R. Wexler
  • Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-&agr; converting enzyme (TACE)
    Patent number: 6770647
    Abstract: The present application describes to novel bicyclic hydroxamates derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, B1, B2, R1, and C are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: August 3, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James E. Sheppeck, Jingwu Duan
  • Asymmetric synthesis of amino-pyrrolidinones
    Patent number: 6770763
    Abstract: A novel process for the asymmetric synthesis of an amino-pyrrolidinone of the type shown below from appropriate pyrrolidinones is described. These compounds are useful as intermediates for MMP and TACE inhibitors.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: August 3, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas A. Magnus, Pasquale N. Confalone, Scott A. Savage, Matthew Yates, Robert E. Waltermir, David J. Meloni, Silvio Campagna
  • 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
    Patent number: 6750225
    Abstract: The present application describes 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones of the following formula or pharmaceutically acceptable salt forms thereof: wherein ring Rb is 3-amido or 4-methoxy, Ra can be cyano, trifluoromethyl, or amido, and R can be a substituted phenyl, a substituted imidazolyl, or a substituted pyridine. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: June 15, 2004
    Assignee: Bristol-Myers Squibb Pharms Company
    Inventors: Donald Joseph Philip Pinto, Robert Anthony Galemmo, Jr., Michael James Orwat, Mimi Lifen Quan
  • Efficient process for the preparation of a factor Xa inhibitor
    Patent number: 6747158
    Abstract: The present invention relates to the process for the preparation of the compound of Formula I: from its corresponding 3-cyano-4-fluorophenyl-pyrazole and intermediates useful therein.
    Type: Grant
    Filed: May 7, 2003
    Date of Patent: June 8, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Hui-Yin Li, Luigi Anzalone, Fuqiang Jin, David J. Meloni, Jung-Hui Sun, Lucius T. Rossano, Christopher A. Teleha, Jiacheng Zhou, Thomas E. Smyser
  • Cyclic &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr;
    Patent number: 6743807
    Abstract: The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 1, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco, Zhonghui Lu, Thomas P. Maduskuie, Jr., Chu-Biao Xue
  • Spiro-cyclic &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr; converting enzyme (TACE)
    Patent number: 6720329
    Abstract: The present application describes novel spiro-cyclic &bgr;-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), and/or aggrecanase inhibitors.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: April 13, 2004
    Assignee: Bristol-Myers Squibb Pharma
    Inventors: Gregory R. Ott, Xiao Tao Chen, Jingwu Duan, Matthew E. Voss
  • Nitrogen containing heterobicycles as factor Xa inhibitors
    Patent number: 6716841
    Abstract: This invention relates generally to nitrogen containing heterobicycles of formulas A and B: which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: April 6, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Irina C. Jacobson, Mimi L. Quan
  • Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
    Patent number: 6710058
    Abstract: The present application describes monocyclic or bicyclic carbocycles and heterocycles and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: March 23, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Irina C. Jacobson, Ruth R. Wexler, Shuaige Wang, Joanne M. Smallheer
  • 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones as factor Xa inhibitors
    Patent number: 6706730
    Abstract: The present application describes 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones of Formula I or pharmaceutically acceptable salt forms thereof: wherein ring R is 3-amido or 4-methoxy, R1 is trifluoromethyl or amido, and R2 is aminomethyl, N-methylaminomethyl, and N,N-dimethylaminomethyl. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: March 16, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Donald Joseph Philip Pinto
  • Amide derivatives as inhibitors of matrix metalloproteinases, TNF-&agr;, and aggrecanase
    Patent number: 6689771
    Abstract: The present application describes novel amides and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein these compounds are useful as inhibitors of matrix metalloproteinases, TNF-&agr;, and aggrecanase.
    Type: Grant
    Filed: February 12, 2002
    Date of Patent: February 10, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Carl P. DeCicco, David J. Nelson, Chu-Biao Xue
  • Aryl sulfonyls as factor Xa inhibitors
    Patent number: 6689770
    Abstract: The present application describes aryl sulfonyls of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein D, E, and M are defined below, are effective factor Xa inhibitors.
    Type: Grant
    Filed: February 12, 2002
    Date of Patent: February 10, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Ruth R. Wexler, Irina C. Jacobson
  • Imidazo-heterobicycles as factor Xa inhibitors
    Patent number: 6673810
    Abstract: The present application describes imidazo-heterobicycles of formulas I and III: or pharmaceutically acceptable salt or prodrug forms thereof. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: January 6, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Patrick Y. Lam, Charles G. Clark, Qi Han, Thomas E. Richardson
  • Efficient process for the preparation of a factor Xa inhibitor
    Patent number: 6667332
    Abstract: The present invention relates to the process for the preparation of the compound of Formula I: from its corresponding 3-cyano-4-fluorophenyl-pyrazole and intermediates useful therein.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: December 23, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hui-Yin Li, Luigi Anzalone, Fuqiang Jin, David J. Meloni, Jung-Hui Sun, Christopher A. Teleha, Jia C. Zhou, Thomas E. Smyser
  • 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
    Patent number: 6642255
    Abstract: The present application describes novel 1,2-disubsituted cyclic derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-8 membered non-aromatic ring consisting of: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, NR2, and S(O)p and the other variables are defined in the present specification, which are useful as metalloprotease and as TNF-&agr; inhibitors.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: November 4, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Chu-Biao Xue, Carl Decicco, Xiaohua He